A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

Key facts

Sponsor

Hoffmann-La Roche

Principal Investigator

Clinical Trials

Hoffmann-La Roche

Intervention

Polatuzumab Vedotin(drug)

Enrollment

1000 enrolled

Eligibility

18-80 years · All sexes

Timeline

2017 – 2026

Study locations (30)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• Southern Cancer Center, Daphne, Alabama, United States
• City of Hope, Duarte, California, United States
• Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
• Rocky Mountain Cancer Centers, LLP, Aurora, Colorado, United States
• Georgetown University Medical Center, Washington D.C., District of Columbia, United States
• Florida Cancer Specialists - Fort Myers (New Hampshire Ct), Fort Myers, Florida, United States
• Florida Cancer Specialists & Research Institute, St. Petersburg, Florida, United States
• Florida Cancer Specialists, West Palm Beach, Florida, United States
• Emory University, Atlanta, Georgia, United States
• Illinois Cancer Specialists, Arlington Heights, Illinois, United States
• University of Louisville Hospital, Louisville, Kentucky, United States
• Ochsner Medical Center, New Orleans, Louisiana, United States
• University of Maryland, Baltimore, Maryland, United States
• Johns Hopkins University, Baltimore, Maryland, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Diffuse large B-cell lymphoma with chronic inflammation

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT07538180
  Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL
  Sun Yat-sen University
• RECRUITINGNCT07070648
  Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
  Fudan University
• RECRUITINGPHASE1, PHASE2NCT06829771
  Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• RECRUITINGPHASE3NCT06717347
  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE2NCT06687772
  CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
  Washington University School of Medicine
• RECRUITINGPHASE1, PHASE2NCT06760039
  Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
  Sun Yat-sen University
• RECRUITINGPHASE2NCT06701357
  CR-CHOP+X in Previously Untreated DEL
  Ruijin Hospital
• RECRUITINGPHASE2NCT06664411
  Pola-ZR2P in Previously Untreated DLBCL
  Navy General Hospital, Beijing

See all trials for Diffuse large B-cell lymphoma with chronic inflammation →